Member Info for biffbaffboff

- what are we waiting for? - confirmation of "Group-wide cost savings", an idea of what "Kirkstall's accelerating sales" brings to the table, and confirmation that "IB's next-generation platforms creates a clear path to profitability in 2026."

-- what are we hoping for? - the above confirmation via more frequent trading updates. Possibly a quarter update?

-- timeline - "profitability in 2026"

Literally their words.

This doesn't look good. Board need to come out to say they see no reason for the drop, unless there is a reason and we'll find out soon enough.

I can't find any trade at 5p, but the ask did hit 5p a few times for short periods last Friday.

FWIW i read it that Mobico is targeting £75m of in-year savings in 2026 (overall), but by the end of 2026 a run-rate of £100 million i.e. approximately £8.3m per month average or £100m over 2027.

FWIW i read it that Mobico is targeting £75m of in-year savings in 2026 (overall), but by the end of 2026 a run-rate of £100 million i.e. approximately £8.3m per month.

We had several good news releases last year: partnerships with Regina Maria in Romania; BUPA UK; Pfizer study; collaboration with Google Cloud; double PSE orders, Third-party partnering/collaboration discussions etc. etc.

This year: Nothing.

I'm not a clown (hate them, give me the heebie-jeebies) but I'm approximately 8% up. Topping up around this level too.

We should get a Half Year Update or Interim Results anytime now. Were 18th June & 30th June last two years.

So, I can't say I am not a little confused. Wasn't it in January that the "directors believe it is no longer in shareholders' interests to embark on a Phase 2 clinical trial of gallium maltolate as previously intended. The financial and operational resources would be better employed to concentrate upon nearer-term commercial objectives of our imaging solutions."

Are we now embarking on a Phase 2 clinical trial of gallium maltolate as previously intended? Or am I missing something?

One of my other investments:

".... invites private shareholders for drinks and Q&A in central London on ...."

"The occasion is a chance to discuss how ####### is progressing these projects towards meaningful value....."

We wait for Tim's invite!

"Why are so many holders still here if you hate the company so much. It has finally gaining traction towards cashflow and is priced to fail which at this stage makes no sense to me."

Many of us don't hate the company, and being 80% - 90% down, many of us have decided that it isn't worth it to sell up now. What we want to see is the BOD running the company properly. It is our money that has funded other pursuits whilst the core of the business still isn't breaking even. Concentrate on that for a while. Release some good figures showing a profit. Raise the SP., then ask for funds with a prospective outlook to progress the company. At the moment, it feels like they need funds to keep the lights on, but are stringing us along with "the Board is confident the Group is entering a period of revenue acceleration. Our expectation of progress towards profitability in 2026 is unchanged."

Show us the figures then!

Is the German agreement still an agreement in principle.? Still risks I guess.

I will be voting against this resolution. They need to focus on the core business.

"The Group meets its day to day working capital requirements through its revenue generating cash flows, discrete fund raises and the issue of convertible loan notes. No such fund raises and issues of convertible loans are planned at this time as these are not currently required. "

Therefore, get the SP above 1p before asking for any more raises.

AI Overview:

There is no clinical difference between the terms immune normaliser (UK spelling) and immunonormalizer (US spelling). Both are used interchangeably in modern immuno-oncology and autoimmune therapy to describe treatments designed to restore healthy immune function rather than over-stimulating or broadly suppressing it.

Do you not think if they had positive news it would warrant a RNS!?

Well, yes, that's the frustration, hasn't been anything positive for a while now. Even a positive outlook would be welcome.

Maybe we'll get something positive with the interims.

The lack of news, or any updates is frustrating.

Only another 2.8% and IBAI will be on the top of the riser board. I might be buy a few more just to help it get there. Average down!

I don't profess to understand it all, but It does raise questions around the recent Phase 1 Trial of Gallium Maltolate in Recurrent Glioblastoma, subsequently discussed as "sponsored" and how a completely different entity can now do another Phase 1 Trial of Gallium Maltolate in Recurrent Glioblastoma but in pediatrics.

I think you might be right. There are blurred lines between Michael and Kathleen with regards to Imaging biometrics and the MCW. If we don't actually own the rights, but are only licensing the use of, then this is only ever going to be worth what we can sell, rather than the asset itself. And it's proving more difficult to increase sales.